Paula Riedel - Partner


PDF Print Friendly Page
Paula Riedel

Download V-Card

Phone: +44 20 7469 2470
Fax: +44 20 7469 2001
Overview News Publications

Professional Profile

Paula Riedel is a partner in Kirkland’s London office. She represents clients before the European Commission and the UK’s Competition and Markets Authority. Her practice spans the full spectrum of antitrust requirements, in particular EU and multinational merger control, antitrust, state aid, compliance and regulatory matters.

Paula is recognized as a leading lawyer in Chambers Global, Chambers Europe and Chambers U.K. She is a long-standing tutor on King’s College London’s Postgraduate Diploma in EU Competition Law and is a former Chair of the Law Society Competition Section. Prior to partnership, she was seconded to the UK’s Department of Trade and Industry, Competition Policy Directorate (Merger Policy).

Paula was elected to partnership at Linklaters LLP in 2003 and prior to joining Kirkland was head of the London Competition Group at Linklaters.

Representative Matters

Selected representative transactions:

  • Ontario Teachers' Pension Plan on the sale of OTPP's majority investment in Helly Hansen to Canadian Tire Corporation for C$985 million (2018)

  • CapVest/IBA Molecular – Carve-out acquisition from Mallinckrodt Plc of its global nuclear imaging radiopharmaceuticals division (2017)

  • Solera – a digital technology group part owned by Vista Equity Partners, on its £340m acquisition of Autodata, a UK provider of digital solutions to the automotive industry, from Bowmark Capital and Rothschild & Co's Five Arrows Principal Investments (2017)

  • Tronox Limited – Acquisition of Cristal’s titanium dioxide business in a cash-and-stock transaction valued at approximately $2.2 billion (2017)

  • Huntsman Corporation in its proposed merger with Clariant with a combined enterprise value of approximately $20 billion (2017)

  • Oaktree Capital Management on the carve out and sale of its UK student housing business to a consortium of GIC, Singapore’s sovereign wealth fund, and global student accommodation firm GSA (2017)

  • Accenture plc – EU clearance for $830 million disposal of Navitaire to Amadeus following referral up to EU by four Member States (2015)

  • Greene King plc – CMA clearance for $1.2 billion takeover of Spirit plc (2015)

  • Qatar Holding – EU and multijurisdictional clearances on a joint $900 million investment in American Express’ global business travel unit (2014)

  • Britvic plc – CC clearance for planned $1.4 billion merger with Barr plc (2013)

  • Allianz AG and Borealis Infrastructure – EU clearance on $1.5 billion acquisition of Net4Gas s.r.o. (2013)

  • Balfour Beatty plc – EU clearance for £190 million sale of its Facilities Management division to GDF Suez Energy Services (2013)

  • Oaktree Capital/Marathon Asset Management – EU clearance for acquisition of control of Fitness First Ltd (2012)

  • Bright Foods Group – multijurisdictional clearances for $1.9 billion acquisition of joint control of Weetabix Ltd (2012)

  • De Beers Group – EU and multijurisdictional clearances for $5.1 billion buyout by Anglo American plc (2012)

  • Qatar Holdings – EU clearance for $1.45 billion investment in Heathrow Airport (2012)

  • Royal Bank of Scotland Group plc – mandated disposals of its interests in Sempra Energy to JP Morgan, in WorldPay to Advent International and Bain Capital and in the Williams and Glyn branch bank business (2010-2014)

  • Makro Ltd – OFT clearance of joint purchasing agreement (2010)

  • Centrica plc – OFT clearance for $3 billion investment in British Energy (2009)

  • Borealis Infrastructure and Ontario Teachers Pension Plan – merger control aspects of their $3.4 billion joint acquisition of a long term concession in HS1 Ltd (2009)

  • Hastings Funds Management – CC clearance for $1.2 billion acquisition of South East Water Ltd (2007)

  • Britvic plc – Irish Competition Authority clearance for $336 million acquisition of the Cantrell & Cochrane soft drinks business (2007)

  • Royal Bank of Scotland Group plc – EU and multijurisdictional clearances for the $100 billion consortium bid for ABN AMRO NV (2007)

  • Rentokil – EU clearance for $1.2 billion acquisition by UTC of its electronic security, alarm monitoring, fire detection and alarm businesses (2007)

  • Pliva – multijurisdictional clearances for $2.5 billion acquisition by AG Barr (2006)

  • DP World – OFT and multijurisdictional clearances for $5.7 billion takeover of P&O Ports (2006)

  • Allied Domecq plc – EU and multijurisdictional clearances for $14 billion takeover by Fortune Brands and Pernod Ricard (2005)

  • Macquarie Bank – regulatory and merger control aspects in relation to its $600 million acquisition of South East Water Ltd (2003)

  • Logica plc/CMG – EU clearance for $1.5 billion messaging platforms merger (2002)

Selected representative antitrust/regulatory:

  • Royal Bank of Scotland Group plc in relation to the EU clearance for the UK Government’s $70 billion aid package (2009 and 2014)

  • Thames Water Ltd in relation to the 2015/2020 wholesale and retail price control (PR14)

  • Antitrust matters in relation to the structuring of The Green Deal Finance Company (2013)

  • De Beers Group in European court proceedings overturning challenges to its global distribution system (2012)

  • A major pharmaceutical company in the CMA antitrust investigation into paroxetine (2011 on)

  • An investment bank in the EU investigation into Credit Default Swaps (2011 on)

  • A global energy company in relation to its world-wide competition compliance audit (2009)

  • Balfour Beatty plc in the OFT antitrust investigation in the construction sector (2006-2009)

  • Office of Rail Regulation in its abuse of dominance proceedings against EWS Ltd (2006)

Memberships & Affiliations

  • Law Society Competition Section (Committee member and former chair)

  • Participant on working groups of the IBA Antitrust Committee

Other Distinctions

Paula Riedel’s clients “value her calm demeanour and approachable attitude”

Chambers UK, 2015


  • EU Antitrust vs. U.S. Companies. (Law360 February 2016, co-authored with Sarah Jordan and James Mutchnik)

  • The Pharma Sector: A route map to merger control in the EU and beyond (MLEX October-December edition 2012, co-authored with Jonathan Ford)

  • The Competition and Markets Authority:  A new era for competition law enforcement in the UK (Competition Policy International 2012, co-authored with Anna Mitchell)

  • Patent Settlements: Post-operative care is now required (Competition Law Insight, 2012)

  • UK Competition Reform (Competition Law Insight, 2011, co-author)

  • Review of the Cave Report: Is water ready for competition (Utility Law Review 2009,  co-authored with Natura Gracia)

  • Competition Settlements: Towards an OFT Policy (Competition Law Insight 2007, co-authored with Sharon Horwitz)

  • The ECJ ruling in Bayer: Commission suffers setback in its pursuit of the Single Market (2004)


  • IBC Legal, UK Competition Law 2015: Chapter I and Chapter II Update

  • GCR Live 4th Annual Antitrust Leaders Forum Miami 2015: A Retrospective on the Term of Commissioner Joaquin Almunía, and a Look Ahead (Chair of Panel)

  • EU Pharmaceutical Law Forum 2014: Reverse Payment Patent Settlements

  • GCR Live Competition Law and Financial Markets 2013: Focus on the CDS Investigation

  • EU Pharmaceutical Law Forum 2012: A review of recent developments in the EU and elsewhere

  • LexisNexis webinars: Merger Control and the Risks of Non-Notification following Electrabel and Marine Harvest (2014); Private enforcement of competition law (2012); Reforms to Merger Control – Chair (2012)

  • BIICL 10th Anniversary Merger Conference 2012 – Recent developments in EU merger control (Chair of Panel)

  • GCR Live Pharmaceutical and Competition Law 2011 – Settlements

  • IBC Advanced EC Competition Law, 2010, 2007, 2006, 2004: Merger case review

  • British Institute of International and Comparative Law 2006: Conceptual and empirical issues in the analysis of local competition: Challenges for the merging parties

  • SMI Pharmaceutical Law 2005 – A Global Perspective: Recent EC cases

© 2018 Kirkland & Ellis LLP